WednesdayNov 18, 2026 1:00 pm

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Advances Peptide Innovation and GLP-1 Companion Strategy

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT) is positioning to capitalize on potential changes in U.S. peptide regulations that could expand access through specialty pharmacies and telehealth platforms. As the FDA considers allowing additional peptides for pharmacy compounding, the company plans to differentiate itself by developing proprietary peptide formulations and delivery technologies designed to improve stability, absorption, administration and performance. Adaptogenics has also acquired nutritional research assets from Berkwood Research to support a GLP-1 companion initiative focused on preserving muscle mass, strength and metabolic health during medically induced weight loss. Recent leadership…

Continue Reading

ThursdayNov 12, 2026 1:37 pm

BioMedNewsBreaks – Earth Science Tech Inc. (ETST) Leverages Vertically Integrated Business Model to Drive Growth and Profitability

Earth Science Tech (OTCQB: ETST) is leveraging its diversified conglomerate business model to build a vertically integrated healthcare platform while expanding its presence across real estate, asset management and consumer products. Its healthcare operations combine compounding pharmacies, telemedicine, clinical support and direct-to-patient fulfillment, supported by internal technology, proprietary physician networks and owned real estate. The company’s acquisition of Zoolzy LLC, a wholesale distributor of active pharmaceutical ingredients and FDA-approved prescription products, further strengthens supply chain control and provides its pharmacies with access to competitively priced ingredients. By bringing more operational functions in-house and leveraging the capabilities of its subsidiaries, Earth…

Continue Reading

ThursdayNov 12, 2026 1:08 pm

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Positions for Emerging Peptide Market with Focus on Quality, Traceability

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT) is positioning itself to address growing demand for quality assurance and transparency in the emerging regulated peptide market through a strategy focused on dependable supply, documented traceability, independent third-party verification and science-based product development. As U.S. regulators consider expanding access to certain compounded peptides while raising concerns about product purity, impurities and safety, the company plans to establish a U.S.-based, GMP-standard supply network using qualified manufacturers and independent laboratories to verify peptide identity and quality. Led by CEO Dr. J. David Warren, a medicinal and…

Continue Reading

ThursdayNov 05, 2026 2:43 pm

BioMedNewsBreaks – Earth Science Tech Inc. (ETST) Builds Long-Term Value Through Strategic Integration

Earth Science Tech (OTCQB: ETST), a diversified holding company operating across healthcare, pharmacy, technology, telemedicine, real estate, and consumer products, is leveraging synergies among its subsidiaries to support long-term growth and generate dependable revenue. Its real estate and asset management subsidiary, Avenvi LLC, contributes to this strategy through its diversified real estate portfolio, property development expertise, and financing solutions for property purchasers. In addition to managing investments and overseeing ETST’s share repurchase program, Avenvi provides essential physical infrastructure for the company’s expanding pharmacy operations, including housing the standalone Mister Meds compounding pharmacy in Texas. Through its real estate capabilities, disciplined…

Continue Reading

ThursdayNov 05, 2026 2:06 pm

BioMedNewsBreaks – Why Adaptogenics Health Corp. (CSE: ADPT) Is ‘One to Watch’

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT) was featured in a recent article that discussed its efforts to build a healthcare company focused on opportunities across the rapidly evolving peptide sector, combining proprietary therapeutic development, pharmaceutical-quality supply infrastructure and innovative drug delivery technologies. “As demand for solutions addressing metabolic health, muscle preservation, recovery and healthy ageing continues to grow, Adaptogenics is positioning itself to address significant healthcare challenges while pursuing opportunities in the expanding market for high-quality peptide development and supply,” the article reads. “The company’s strategy combines experienced pharmaceutical leadership, scientific…

Continue Reading

FridayOct 30, 2026 1:59 pm

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands NAMs Strategy to Advance BiTAC(R) Therapies

VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant preclinical testing methods across its antibody-based cancer drug development programs, aiming to improve the clinical relevance of research findings while reducing animal testing. The company is implementing New Approach Methodologies (“NAMs”), including three-dimensional tumor spheroid models and patient-derived tumor models, in support of its BiTAC(R) T-cell engagers, antibody-drug conjugates and bispecific antibody-drug conjugates. VERAXA reported that its lead BiTAC T-cell engager demonstrated selective, potent T-cell-mediated tumor-cell killing across 10 patient-derived non-small cell lung cancer models, while relevant controls showed minimal activity. The ex vivo study required approximately 10 mice, compared…

Continue Reading

FridayOct 30, 2026 1:00 pm

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Taps Thermo Fisher’s Clinical Research Business for Lucid-MS Trial

Quantum BioPharma (NASDAQ: QNTM) has signed a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business to support the Phase 2 clinical trial of Lucid-MS, its investigational drug candidate for progressive multiple sclerosis (“MS”). Following U.S. Food and Drug Administration clearance of its Investigational New Drug application in August 2026, the agreement moves the program toward clinical implementation with a contract research organization experienced in central nervous system and MS studies. Unlike many existing MS treatments that primarily target the immune system, Lucid-MS is designed to protect myelin, the protective coating around nerve fibers, by inhibiting PAD2, an enzyme…

Continue Reading

ThursdayOct 29, 2026 2:21 pm

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Highlights Potential of GelrinC Cartilage Repair Technology

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed the company’s efforts to advance its regenerative cartilage repair technology, GelrinC, as orthopedic medicine increasingly emphasizes durable, long-term treatment outcomes. The company’s lead product is a cell-free, off-the-shelf degradable hydrogel implant designed to support the regeneration of knee cartilage, gradually resorbing over approximately six to nine months as new tissue fills the treated area. Regentis reports that its Pilot/Phase II study showed 100% greater pain improvement compared with traditional microfracture treatment, while 24-month follow-up results showed a mean MOCART score of 88.8 out of 100, an MRI-based measure…

Continue Reading

WednesdayOct 28, 2026 12:57 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Brings AI and In-House Expertise to Enhance Operational Efficiency

Earth Science Tech (OTCQB: ETST) is leveraging artificial intelligence (“AI”), proprietary software and its in-house IT expertise to improve operational efficiency, reduce costs and support sustainable growth across its pharmacy and telemedicine businesses. Led by Chief Technology Officer Chris Rose, the company has developed an integrated software and data platform connecting its pharmacies, curative telehealth business and My Online Consultation physician network. The platform automates administrative workflows and supports functions such as inventory, invoicing, shipping and purchasing, while creating opportunities to offer its technology to other clinics as a white-label service. ETST also uses customer relationship management systems and proprietary…

Continue Reading

WednesdayOct 21, 2026 3:00 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Aims for Greater Precision in Cancer Therapy

VERAXA Biotech (NASDAQ: VRXA) is developing antibody-based cancer therapies designed to improve treatment selectivity and potentially reduce toxicity to healthy tissues. At the center of its strategy is the proprietary BiTAC (Bi-targeted Tumor-Associated Cytotoxicity) platform, which uses two complementary molecules designed to activate cancer-killing activity only when both recognize targets on the same tumor cell. The company is applying this approach to antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), with a particular focus on solid tumors. VERAXA reported promising preclinical findings for its lead BiTAC-TCE program, including selective targeting of cells expressing both intended targets and improved safety alongside comparable…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000